Before a crowded auditorium of science and business professionals at the Frederick National Laboratory for Cancer Research’s (FNLCR) Advanced Technology Research Facility (ATRF), Joost Oppenheim, M.D., had just finished his presentation about a compound that has the potential to expand the impact of a promising category of cancer therapeutics when he fielded a question from Stephan Stern, Ph.D. 

Gene editing using the powerful new CRISPR-Cas9 system is showing promise as a tool for developing potential treatments for inherited diseases, particularly for those caused by single genetic defects.

Four recent studies have given the scientific community a better understanding of how human immunodeficiency virus (HIV) establishes and maintains itself in an infected individual and how antibody therapy may help prevent or fight the disease.

Biotechnology stakeholders from across the region will have the opportunity to learn about cutting-edge technologies addressing urgent and intractable problems in cancer research at the 2017 Technology Showcase, to be held at the Frederick National Laboratory’s (FNL) Advanced Technology Research Facility (ATRF).

The Frederick National Laboratory for Cancer Research’s Vaccine Pilot Plant, part of the Vaccine Clinical Materials Program (VCMP), is helping researchers produce investigational Zika vaccines for a new round of clinical trials.

Two government agencies and five national laboratories are collaborating to develop extremely high-performance computing capabilities that will analyze mountains of research and clinical data to improve scientific understanding of cancer, predict drug response, and improve treatments for patients.

For speeding the delivery of an effective candidate vaccine during the largest Ebola outbreak in history, the Frederick National Lab (as Leidos Biomed) was cited along with National Institute of Allergy and Infectious Diseases and GlaxoSmithKline in winning an Excellence in Technology Transfer Award from the Federal Laboratory Consortium for Technology Transfer.

Scientists have discovered an efficient and straightforward model to manipulate RNA nanoparticles, a new concept that could help trigger desirable activation of the immune system with vaccines and therapies.

A multi-institutional team of researchers used an approach to fine tune DNA and RNA nanoparticles to activate multiple biological functions and pathways. The group recently published its findings in Nucleic Acids Research.

Pages